Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04894435 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

Study acronym: MOSAIC
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Nov 2024 to Nov 15, 2024
    • Study completion date: Feb 2025 to Aug 1, 2025
    v11
  2. Primary completion date: Mar 2024 to Nov 2024
    • Study completion date: May 2024 to Feb 2025
    v10
  3. Primary completion date: Oct 2023 to Mar 2024
    • Study completion date: Mar 2024 to May 2024
    v9
  4. Primary completion date: Mar 2023 to Oct 2023
    • Study completion date: Sep 2023 to Mar 2024
    v8
  5. Secondary endpoints: 12 to 14v7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary endpoints: 3 to 4v6 Show 10 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 1060 to confirmed 669
    • Study completion date: Apr 2023 to Sep 2023
    • Interventions: 0, 112 day schedule (Other), 0, 28 day schedule (Other), BNT162b2 (Biological), ChAdOx1-S [recombinant] (Biological), mRNA-1273 SARS-CoV-2… to 0, 112 day schedule (Other), 0, 28 day schedule (Other), BNT162b2 (Biological), ChAdOx1-S [recombinant] (Biological), Covifenz…
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: 8 to 12
    • Study description expanded, about 49 words
    • Study sites revised (8)
    • Collaborators: 9 to 10
    • Study arms: 20 to 28
  2. Site details revised at 5 of 8 sitesv5
  3. Primary endpoints: 2 to 3v4 Show 8 more changesShow less
    • Enrollment target: 1200 to 1060
    • Study completion date: Mar 2023 to Apr 2023
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: 4 to 8
    • Study description expanded, about 42 words
    • Site details revised at 4 of 8 sites
    • Study arms: 12 to 20
    • Study title shortened, about 2 words
  4. Study sites: 6 to 8
    • Eligibility criteria revised
    • Collaborators revised (9)
    v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Enrollment target: 1300 to 1200
    • Start date changed from estimate of May 2021 to May 20, 2021
    • Eligibility criteria shortened, about 26 words
    • Site details revised at 6 of 6 sites
    • Study arms: 13 to 12
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose vaccines.
Trial Details
NCT Number NCT04894435
Lead Sponsor Canadian Immunization Research Network
Collaborators: Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions
(from sponsor)		 COVID-19
Related terms COVID-19
Enrollment 669 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov